Current status and prospects of live varicella vaccine.
Since its development in 1974 the Oka strain live attenuated varicella vaccine has been tested in healthy and immunocompromised adults and children. Its safety and efficacy have been established and it is now licensed for general use in Japan and Korea, and for immunocompromised patients in several other countries. Possibilities for the future include its use to prevent zoster in the elderly, its incorporation in a multivalent vaccine and its use as a vehicle to express foreign genes in recombinant vaccines.
Takahashi
M
M
Research Institute for Microbial Diseases, Osaka University, Japan.
D000328:Adult; D000368:Aged; D002644:Chickenpox / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D019433:Chickenpox Vaccine; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004279:DNA, Viral / Q000235:genetics; D005544:Forecasting; D006562:Herpes Zoster / Q000453:epidemiology / Q000517:prevention & control*; D014645:Herpesvirus 3, Human / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D007564:Japan; D007723:Korea; D007938:Leukemia / Q000150:complications; D008875:Middle Aged; D014481:United States / Q000453:epidemiology; D014611:Vaccination / Q000009:adverse effects / Q000706:statistics & numerical data; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D014614:Vaccines, Synthetic; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D014774:Virulence
D019433:Chickenpox Vaccine; D004279:DNA, Viral; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines